Zura Bio Ltd (ZURA)

Dec 23, 2024, 6:30 AM EST - 2 months ago

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Nov 25, 2024, 6:30 AM EST - 3 months ago

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 3 months ago

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Nov 7, 2024, 6:30 AM EST - 3 months ago

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Oct 30, 2024, 6:30 AM EDT - 4 months ago

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Sep 3, 2024, 6:00 AM EDT - 6 months ago

CPS HR Consulting Partners with GovInvest to Revolutionize Compensation Consulting with Advanced Technology

OGI

Sep 3, 2024, 6:00 AM EDT - 6 months ago

Zura Bio to Present at Three Upcoming Investor Conferences in September

Aug 13, 2024, 9:21 AM EDT - 6 months ago

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 12, 2024, 4:05 PM EDT - 6 months ago

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Aug 9, 2024, 4:05 PM EDT - 7 months ago

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Jul 12, 2024, 6:10 AM EDT - 8 months ago

Zura Bio Commences Warrant Exchange Offer and Consent Solicitation

Jun 14, 2024, 6:00 AM EDT - 9 months ago

Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024

Jun 6, 2024, 6:00 AM EDT - 9 months ago

Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology

Jun 3, 2024, 6:00 AM EDT - 9 months ago

Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024

May 29, 2024, 6:00 AM EDT - 9 months ago

Zura Bio Announces Participation in June Investor Conferences

May 9, 2024, 6:00 AM EDT - 10 months ago

Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 18, 2024, 9:22 AM EDT - 11 months ago

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Apr 8, 2024, 6:00 AM EDT - 11 months ago

Zura Bio Announces Robert Lisicki as CEO and Director

Mar 28, 2024, 6:00 AM EDT - 11 months ago

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Mar 4, 2024, 6:00 AM EST - 1 year ago

Zura Bio Announces Participation at March Conferences

Feb 2, 2024, 6:00 AM EST - 1 year ago

Zura Bio Announces Participation at February Investor Conferences

Jan 8, 2024, 6:00 AM EST - 1 year ago

Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO

Jan 3, 2024, 6:00 AM EST - 1 year ago

Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit

Dec 4, 2023, 6:00 AM EST - 1 year ago

Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok

Nov 14, 2023, 6:00 AM EST - 1 year ago

Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors

Nov 13, 2023, 6:30 AM EST - 1 year ago

Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Sep 12, 2023, 5:00 AM EDT - 1 year ago

Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute

Aug 14, 2023, 7:00 AM EDT - 1 year ago

Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jun 23, 2023, 6:30 AM EDT - 1 year ago

Zura Bio to Join the Russell 2000® and Russell 3000® Indexes

Jun 6, 2023, 4:00 AM EDT - 1 year ago

Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist

Apr 27, 2023, 7:39 AM EDT - 1 year ago

Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases

Apr 14, 2023, 5:00 AM EDT - 2 years ago

Zura Bio Announces Appointment of Chief Scientific Officer

Mar 21, 2023, 6:13 AM EDT - 2 years ago

Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

Mar 16, 2023, 4:17 PM EDT - 2 years ago

JATT Acquisition Corp Shareholders Approve Proposed Business Combination with Zura Bio Limited